Aveo takes bigger 4Q loss on drug development
CAMBRIDGE, Mass. (AP) — Aveo Pharmaceuticals Inc. reported a wider fourth-quarter loss Tuesday as it continued to study its experimental cancer drugs tivozanib and ficlatuzumab.
Aveo said it lost $25.2 million, or 58 cents per share, during the fourth quarter. A year earlier it posted a loss of $10.3 million, or 30 cents per share. Revenue from collaborations with companies like Astellas Pharma and Johnson & Joh...
You have selected to view an article that is older than 60 days. There are several ways to unlock access to NewsOK historical content.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
